PTN

Palatin Technologies Inc

8.13

Jul 22 • 03:44PM ET -0.49 (-5.68%)

Healthcare Biotechnology USA Nano NASD

Peers: BCTX CELU CLRB JSPR LGVN MRKR NXTC PLUR TPST VTGN

Index	-
Market Cap	14.47M
Enterprise Value	4.60M
Income	-6.25M
Sales	12.88M
Book/sh	5.96
Cash/sh	5.71
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Oct 28, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	1.12
P/B	1.36
P/C	1.42
P/FCF	-
EV/EBITDA	-
EV/Sales	0.36
Quick Ratio	5.04
Current Ratio	5.04
Debt/Eq	0.03
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-1.37
EPS next Y	-2.31
EPS next Q	-1.20
EPS this Y	93.50%
EPS next Y	-10.69%
EPS next 5Y	53.79%
EPS past 3/5Y	44.66% 23.09%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.63%
Sales Y/Y TTM	3581.22%
EPS Q/Q	95.99%
Sales Q/Q	-
Earnings	May 13 BMO
EPS/Sales Surpr.	70.24% 207.04%

Insider Own	9.10%
Insider Trans	0.00%
Inst Own	55.09%
Inst Trans	2.91%
ROA	-73.72%
ROE	-297.24%
ROIC	-58.46%
Gross Margin	-3.40%
Oper. Margin	-68.70%
Profit Margin	-48.50%
SMA20	-17.95%
SMA50	-34.86%
SMA200	-48.41%
Trades

Shs Outstand	1.78M
Shs Float	1.62M
Short Float	11.27%
Short Ratio	10.99
Short Interest	0.18M
52W High	31.00 -73.77%
52W Low	5.00 62.60%
Volatility	10.50% 10.08%
ATR (14)	0.95
RSI (14)	31.30
Beta	0.58
Rel Volume	0.25
Avg Volume	16.61K
Volume	3,918

Perf Week	-8.65%
Perf Month	-30.93%
Perf Quarter	-62.79%
Perf Half Y	-51.64%
Perf YTD	-47.14%
Perf Year	-6.03%
Perf 3Y	-92.07%
Perf 5Y	-98.77%
Perf 10Y	-98.86%
Recom	1.00
Target Price	53.50
Prev Close	8.62
Price	8.13
Change	-5.68%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Laidlaw	Buy	$60
Dec-03-25	Initiated	Alliance Global Partners	Buy	$50

Today 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire) -5.68%
May-18-26 04:00PM	Palatin to Begin Trading on Nasdaq Stock Exchange (PR Newswire) +5.76% -6.36%
May-13-26 07:03PM	Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -16.01% -9.82%
07:30AM	Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Feb-18-26 08:30AM	Palatin Technologies, Inc. Q2 2026 Earnings Call Summary (Moby) +10.01%
06:00PM	Loading…
Feb-17-26 06:00PM	Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
07:30AM	Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-13-25 07:30AM	Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-25 12:15PM	Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option (PR Newswire) +29.43%

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Co-FounderDr. Carl Spana Ph.D.

MSTMr. Stephen T. Wills CPA

Vice President of Investor RelationsBurns McClellan

Chief Legal OfficerMr. Stephen A. Slusher Esq.

M.S.Mr. James E. Hattersley B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Dec 24 '25	Sale	16.74	565	9,461	63,488	Dec 29 04:30 PM
WILLS STEPHEN T	Director	Dec 24 '25	Proposed Sale	16.74	565	9,461		Dec 29 10:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your Finviz experience